Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.39 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18786517 | 0.96 | PTGS1 (0.42) | PTGS1PTGS2MGLLFAAHGNAI3 | |
| SCHEMBL45798 | 0.94 | MGLL (0.39) | PTGS1PTGS2MGLLFAAHGNAI3 | |
| Alcohol SCHEMBL28659728 | 0.88 | NPC1 (0.36) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL4270831 | 0.79 | TSHR (0.47) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL4270037 | 0.79 | TSHR (0.47) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL4274617 | 0.79 | TSHR (0.47) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL18838747 | 0.77 | NPC1 (0.44) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL4272553 | 0.75 | NPC1 (0.43) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL665738 | 0.75 | NPC1 (0.43) | PTGS1PTGS2MGLLFAAHNPC1 | |
| SCHEMBL4274729 | 0.73 | NPC1 (0.42) | PTGS1PTGS2MGLLFAAHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306184-A | Preparation method of baby wet tissue with sterilizing and moisturizing core | 华药生物科技(浙江)有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20250367165-A1 | EMERGENCY EYE WASH | LEBRUN LABS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250262123-A1 | EMERGENCY EYE WASH | LEBRUN LABS LLC | 2025-08-21 | — | — | US | disclosed |
| EP-3713540-B1 | PLANT BASED OIL-IN-WATER ORAL EMULSIONS AND METHODS OF USE | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | KaNDy Therapeutics Limited (GB) | 2025-05-15 | — | — | US | disclosed |
| CN-119950513-A | Novel pharmaceutical formulations containing dual NK-1/NK-3 receptor antagonists | KaNDy治疗有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12264164-B2 | Method of treatment of symptoms of menopause | KaNDy Therapeutics Limited (GB) | 2025-04-01 | — | — | US | disclosed |
| CN-119571401-A | Environment-friendly cyanide-free zincate galvanization brightening agent and preparation method thereof | 苏州金蚂蚁精密钣金有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-3972698-B1 | ORAL COMPOSITIONS AND METHODS OF USE | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025005348-A1 | ORAL LIQUID COMPOSITION COMPRISING BIFIDOBACTERIUM EXTRACT | 주식회사 고차원 | 2025-01-02 | — | — | WO | disclosed |
| EP-1139981-A4 | COMPOSITIONS AND METHODS OF USING THE SAME | FOUR STAR PARTNERS (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1149190-A2 | SOLUTION AND PROCESS FOR THE ELECTRODEPOSITION OF GOLD AND GOLD ALLOYS | Half Tone Ltd. (IE) | 2001-10-31 | — | — | EP | disclosed |
| US-6306514-B1 | COATING SURFACE OF ELASTOMERIC FLEXIBLE ARTICLE WITH HYDROPHOBIC ACRYLIC-STYRENE RESIN, CURING, HALOGENATING, NEUTRALIZING, TREATING SURFACE WITH LUBRICANT COMPRISING COMBINATION OF SURFACTANTS, ACETYLENIC DIOL, SILICONE | ANSELL HEALTHCARE PRODUCTS INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1139981-A2 | COMPOSITIONS AND METHODS OF USING THE SAME | Four Star Partners (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038617-A2 | COMPOSITIONS AND METHODS OF USING THE SAME | FOUR STAR PARTNERS (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039367-A2 | SOLUTION AND PROCESS FOR THE ELECTRODEPOSITION OF GOLD AND GOLD ALLOYS | HALF TONE LIMITED (IE) | 2000-07-06 | — | — | WO | disclosed |
| EP-0951501-A1 | SLIP-COATED ELASTOMERIC FLEXIBLE ARTICLES AND THEIR METHOD OF MANUFACTURE | ETHICON, INC. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998029484-A1 | SLIP-COATED ELASTOMERIC FLEXIBLE ARTICLES AND THEIR METHOD OF MANUFACTURE | ETHICON, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5742943-A | LUBRICANT FOR SURGEON'S RUBBER GLOVE, SILICONE AND ACETYLENIC DIOL, CATIONIC SURFACTANT | JOHNSON & JOHNSON MEDICAL, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0815880-A2 | Elastomeric flexible articles and their method of manufacture | JOHNSON & JOHNSON MEDICAL, INC. (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264164-B2 | Method of treatment of symptoms of menopause | CYP19A1, MTNR1B, SHBG | PTGS1 355/4885PTGS2 383/4885GAA 3624/4885 |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | CYP19A1, MTNR1B, SHBG | PTGS1 355/4885PTGS2 383/4885GAA 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.